目的 探讨大株红景天注射液联合地尔硫䓬治疗冠心病心绞痛的临床疗效。方法 选取2020年1月-2020年7月在郑州大学第五附属医院诊治的142例冠心病心绞痛患者，随机分为对照组和治疗组，每组各71例。对照组口服盐酸地尔硫䓬片，1片/次，3次/d。治疗组在对照组的基础上静脉滴注大株红景天注射液，每次10 mL加入5%葡萄糖注射液250 mL，1次/d。两组患者均治疗10 d。观察两组患者临床疗效，同时比较治疗前后两组患者心绞痛发作情况、硝酸甘油用量、24 h动态心电图变化，及超敏C反应蛋白（hs-CRP）、可溶性细胞间黏附分子1（sICAM-1）、白细胞介素-6（IL-6）、基质金属蛋白酶-2（MMP-2）、超氧化物歧化酶（SOD）、丙二醛（MDA）和晚期糖基化终末产物（AGEs）水平。结果 治疗后，对照组临床有效率为80.28%，显著低于治疗组的92.96%（P<0.05）。治疗后，两组心绞痛发作次数、心绞痛每次持续时间、硝酸甘油用药总量均显著下降（P<0.05），且治疗组下降幅度更明显（P<0.05）。治疗后，治疗组缺血发作次数、缺血最长持续时间、缺血总时间、室性早搏次数明显低于对照组（P<0.05）。治疗后，两组患者hs-CRP、sICAM-1、IL-6、MMP-2水平均显著下降（P<0.05），且治疗组下降更明显（P<0.05）。治疗后，两组患者SOD显著升高，MDA、AGEs显著下降（P<0.05），且治疗组患者改善更明显（P<0.05）。结论 大株红景天注射液联合地尔硫䓬治疗冠心病心绞痛具有良好的临床疗效，可有效改善患者临床症状，改善冠脉供血，控制炎症反应，抑制氧化应激反应，且安全性较高，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Dazhuhongjingtian Injection combined with diltiazem in treatment of angina pectoris of coronary heart disease. Methods Patients (142 cases) with angina pectoris of coronary heart disease in the Fifth Affiliated Hospital of Zhengzhou University from January 2020 to July 2020 were randomly divided into control and treatment groups, and each group had 71 cases. Patients in the control group were po administered with Diltiazem Hydrochloride Tablets, 1 tablet/time, three times daily. Patients in the treatment group were iv administered with Dazhuhongjingtian Injection on the basis of the control group, 10 mL added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacy was evaluated, and the incidence of angina pectoris, dosage of nitroglycerin, and 24 h ambulatory electrocardiogram, the levels of hs-CRP, sICAM-1, IL-6, MMP-2, SOD, MDA, and AGEs in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.28%, which was significantly lower than 92.96% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the incidence of angina pectoris, dosage of nitroglycerin, and 24 h ambulatory electrocardiogram in two groups were significantly decreased (P<0.05), and the indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the frequency of ischemic attacks, the longest duration of ischemia, the total time of ischemia, the frequency of ventricular premature beats in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of hs-CRP, sICAM-1, IL-6 and MMP-2 in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the SOD levels in two groups were significantly increased, but the MDA and AGEs levels were significantly decreased (P<0.05), and the improvement of SOD, MDA, and AGEs in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Dazhuhongjingtian Injection combined with diltiazem has good clinical efficacy in treatment of angina pectoris of coronary heart disease, can effectively improve the clinical symptoms, improve coronary blood supply, control inflammatory reaction, inhibit oxidative stress reaction, and has high safety, which has a certain clinical application value.

R972